<code id='C269568E04'></code><style id='C269568E04'></style>
    • <acronym id='C269568E04'></acronym>
      <center id='C269568E04'><center id='C269568E04'><tfoot id='C269568E04'></tfoot></center><abbr id='C269568E04'><dir id='C269568E04'><tfoot id='C269568E04'></tfoot><noframes id='C269568E04'>

    • <optgroup id='C269568E04'><strike id='C269568E04'><sup id='C269568E04'></sup></strike><code id='C269568E04'></code></optgroup>
        1. <b id='C269568E04'><label id='C269568E04'><select id='C269568E04'><dt id='C269568E04'><span id='C269568E04'></span></dt></select></label></b><u id='C269568E04'></u>
          <i id='C269568E04'><strike id='C269568E04'><tt id='C269568E04'><pre id='C269568E04'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:hotspot    Page View:59
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In